Tag: Bedfont

Bedfont® Scientific Limited partners with Rymindr to deliver vital classroom supplies

Posted on

Bedfont® ensures exercise books reach UK classrooms through sponsorship.

Bedfont® Scientific Limited, a world leader in breath analysis, with nearly 50 years of expertise in the medical device industry, has teamed up with Rymindr, a social-tech company, to deliver vital classroom supplies. Rymindr is an app that lets users track important dates and access rewards. Through the app, Rymindr helps UK schools save money by sharing its profits. Bedfont® is proud to support its exercise book sponsorship campaign by sponsoring 20 boxes of exercise books, ensuring they reach the classrooms where they are needed.

It has been reported that over 70% of schools in the UK are underfunded1, leading to increased pressure on schools through teacher shortages and reduced resources. Rymindr’s mission is to build a single ecosystem that benefits all, leading to positive impacts on society and the environment for this generation and those to come. They have been funding breakfasts, school meals, and classroom supplies for children.

“We’re thrilled to partner with Bedfont® to get essential classroom supplies into UK schools. With budgets under pressure, simple items like classroom resources from exercise books to pencils shouldn’t be a struggle to fund, and this sponsorship will make a real difference in classrooms across the country.” Said Rav Panesar, CEO of Rymindr. “We’re incredibly grateful to Bedfont® for stepping up and sponsoring. This is exactly the kind of community impact we want to create through Rymindr, bringing businesses and schools together to deliver practical support where it’s needed most.”

Bedfont® is supporting their current initiative to get thousands of brand-new exercise books directly into UK primary schools. Having already distributed 4,000 boxes across the country, Rymindr were unfortunately notified at the end of 2025 that their storage facility was being sold. This has led to the launch of their latest sponsorship campaign, inviting individuals and businesses to sponsor boxes of books. The sponsorship covers the practical logistics, such as storage, pallet handling, and distribution.

Bedfont® Helps Deliver Classroom Supplies

“We’re incredibly proud to support this campaign and help deliver something as fundamental as exercise books to classrooms across the UK.” Said Jason Smith, CEO at Bedfont®. “With so many schools facing funding pressures, it’s vital we step in where we can. By sponsoring these boxes, we’re helping teachers focus on what matters most, teaching, while easing some of the financial strain they face every day. Education is the foundation of our future, and we’re committed to playing our part.”

Rymindr is matching each sponsored box, meaning schools across the UK are saving around £100 per box, which will really make a difference to the already stretched school budgets. Bedfont® is strongly committed to supporting the local community and is pleased to assist Rymindr in its latest initiative, providing much-needed exercise books to UK schools. To find out more about Rymindr, visit the website here. For more information on Bedfont® and its community initiatives, visit the website here.

References

  1. New data finds that 7 in 10 schools in England faced budget cuts since 2010 | National Education Union [Internet]. National Education Union. 2025. Available from: https://neu.org.uk/latest/press-releases/new-data-finds-7-10-schools-england-faced-budget-cuts-2010

The Role of FeNO Testing in Asthma Management

Posted on

Asthma is a chronic lung condition that causes airway inflammation and affects approximately 262 million people worldwide1. Typical symptoms include:

  • Wheezing,
  • Breathlessness,
  • Chest tightness,
  • Coughing.

When airways are inflamed, breathing can become difficult. Recent Asthma + Lung UK research found that over 42,000 people ended up in emergency care in 2023/24 after visiting 5 or more times within the last 12 months2. These startling numbers highlight the importance of better asthma management to reduce the burden on healthcare systems.

Assessing airway inflammation is key to better asthma management. When a person’s airways become inflamed, higher-than-usual nitric oxide (NO) gases are produced. The easiest way to measure a person’s NO levels is a Fractional exhaled Nitric Oxide (FeNO) test.

What is FeNO testing?

A FeNO test with a device like the NObreath® is a quick, easy, non-invasive and accurate way to measure NO levels in exhaled breath. NO is a marker of eosinophilic airway inflammation, common in allergic asthma. Patients follow on-screen instructions to inhale and then exhale into the device, providing instant results.

FeNO levels are measured in parts per billion (ppb). A high FeNO level indicates airway inflammation and can aid in diagnosing asthma.

ATS/ERS Clinical Guidelines Summary for Interpreting FeNO Levels3,4:

Note: These reflect the ATS and ERS guidelines. FeNO interpretation thresholds may vary between guidelines.

FeNO testing with the NObreath®

The NObreath® is a FeNO device manufactured by Bedfont® Scientific Limited. Bedfont® has over 48 years of knowledge and expertise in designing and manufacturing medical breath analysis devices. The NObreath® has improved asthma management for over 15 years, providing healthcare professionals (HCPs) with a fairly priced solution for FeNO testing. Suitable for both adults and children, the NObreath® is perfect for primary and secondary care settings. For more information on the NObreath®, visit the website here.

Why is FeNO testing useful in asthma?

Airway inflammation cannot be seen; FeNO tests allow HCPs to track any underlying inflammation and, when used alongside an extensive clinical history, can diagnose asthma. Having access to a FeNO device is useful throughout the asthma pathway. Not only does it aid an asthma diagnosis, but it also helps to guide treatment decisions.

Carrying out FeNO tests in routine asthma reviews allows HCPs to:

  • Tailor inhaled corticosteroid (ICS) therapy,
  • Identify steroid responsiveness,
  • Guide step-up or step-down treatment strategies.

A patient who consistently presents with a high FeNO level indicates possible poor adherence to ICS, therefore, instigating conversations about medication use.

The Role of FeNO Testing

FeNO testing is incorporated into worldwide guidelines. Joint guidelines by the National Institute of Health Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) now recommend FeNO as a first-line test for asthma diagnosis.

Future of FeNO testing.

The biggest challenge with FeNO testing is accessibility; unfortunately, some areas do not have access to a FeNO device. In a recent interview with Carol Stonham MBE, we discussed the issues around funding. In some areas, the Integrated Care Board (ICB) will pay for it, but in others, it is down to the Primary Care Network (PCN). However, if the PCN does not deem it a priority, it comes down to the individual General Practice (GP) surgeries.

Looking back at the shocking statistics at the beginning of this blog, it is clear that better asthma management is needed. FeNO is a valuable tool in modern asthma management. It guides HCPs to understand the underlying airway inflammation in asthma, leading to better patient outcomes.

With the NICE/BTS/SIGN guidelines update, FeNO testing is recommended as a first-line test for asthma diagnosis and management in adults. This means access to FeNO needs to improve.

For more information on FeNO testing and its central role in asthma care in the joint NICE/BTS/SIGN guidelines, click here to read our article on the guideline updates and FeNO testing.

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. Surge in repeat hospital visits for lung conditions [Internet]. Asthma + Lung UK. 2025 [cited
    2025 Mar 18]. Available from:
    https://www.asthmaandlung.org.uk/media/press-releases/surge-repeat-hospital-visits-lung-
    conditions
  3. Louis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T, Rigau D, Ten Brinke A, Buhl R, Loukides S, Kocks JW. European Respiratory Society guidelines for the diagnosis of asthma in adults. European Respiratory Journal. 2022 Sep 1;60(3). DOI: 10.1183/13993003.01585-202. [cited 2025 May 14] Available from: https://pubmed.ncbi.nlm.nih.gov/35169025/
  4. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American journal of respiratory and critical care medicine. 2011 Sep 1;184(5):602-15. PMCID: PMC4408724 PMID: 21885636. [cited 2025 May 14] Available from: https://pubmed.ncbi.nlm.nih.gov/21885636/

Bedfont® Scientific Limited is pleased to support a major milestone to improve asthma care

Posted on

Intermedical UK proudly delivers the 3,000th NObreath® FeNO device to the UK market.

Bedfont® Scientific Limited, a medical device manufacturer based in Kent, with over 49 years’ experience in the breath analysis industry, was pleased to support its UK distributor, Intermedical UK, in supplying the 3,000th NObreath® Fractional exhaled Nitric Oxide (FeNO) device in the UK. Intermedical UK, a trusted leader in respiratory health, has been providing cardio-respiratory diagnostic and therapy equipment for frontline care since 1997.

Bedfont® support major milestone in asthma care. Bedfont Supports FeNO Milestone.
Bedfont® and Intermedical Team

Livio Gagliardi, Acting Managing Director at Intermedical (UK) Ltd, said, “Reaching the 3,000th NObreath® FeNO device in the UK is a shared success that reflects the dedication of both the Intermedical and Bedfont® teams. Together, we have worked hard to deliver a clinically proven, accessible, and cost-effective FeNO solution that genuinely meets the needs of frontline healthcare. We are incredibly grateful to our customers for placing their trust in us and for recognising the value that NObreath® brings to asthma diagnosis and ongoing management. Their commitment to improving respiratory care is what makes milestones like this possible, and we look forward to continuing this journey of innovation and impact alongside Bedfont®.”

NObreath FeNO device. Bedfont Supports FeNO Milestone.

The NObreath® FeNO device, manufactured by Bedfont®, is an innovative diagnostic tool that measures airway inflammation and helps healthcare professionals diagnose and manage asthma effectively. With over 3,000 devices now available across the UK, access to FeNO testing is improving, bringing Bedfont® closer to a world where everyone can access instant, non-invasive, and simple breath testing to support medical diagnosis.

As a valued long-term distributor of the NObreath®, Intermedical UK has played a key role in expanding access to high-quality respiratory diagnostics, and the close partnership over the years has been instrumental in reaching this monumental milestone.

Jason Smith, CEO at Bedfont®, comments, “This milestone of 3,000 devices in UK primary care highlights just how rapidly objective asthma testing is advancing. The updated joint UK guidelines now place even greater emphasis on FeNO, echoing the global shift toward evidence-based, accessible diagnostic tools. We are committed to making this technology available everywhere it is needed, ensuring clinicians and patients around the world benefit from fast, non-invasive breath testing.”

Bedfont® remains committed to improving asthma care worldwide, working closely with a global network of distributors to expand access to FeNO testing and improve asthma treatment. Recent partnerships in Mexico and India are already strengthening diagnostic capabilities, enabling clinicians in these regions to integrate simple, non-invasive breath testing into routine asthma assessment.

To learn more about Bedfont® and the NObreath® FeNO device, visit the website here.

Bedfont® Scientific Limited is proud to exhibit cutting-edge breath analysis devices at WHX Dubai.

Posted on

Smokerlyzer®, Gastrolyzer®, and NObreath® devices on show at the world’s largest healthcare event.

Bedfont® Scientific, world leaders in breath analysis, with over 49 years of experience in the medical breath analysis industry, is thrilled to be showing its innovative devices at this year’s World Health Expo (WHX) Dubai, from the 9th to the 12th February 2026. Formally known as Arab Health, WHX Dubai has grown into a global healthcare hub, attracting professionals from over 180 countries. The event is due to take place at the Dubai Exhibition Centre.

Bedfont® exhibit at WHX Dubai
Bedfont Team at Arab Health 2025

WHX Dubai represents a cornerstone event for international healthcare collaboration, innovation, investment, and knowledge sharing. Bedfont® is pleased to be demonstrating its devices at the world’s largest healthcare event. On show at stand S7.F90.F, you will find the Smokerlyzer® range of breath carbon monoxide (CO) devices, which aid smoking cessation. The Gastrolyzer® hydrogen-methane breath testing (HMBT) range, which is used to help detect gastrointestinal disorders. And the NObreath® fractional exhaled nitric oxide (FeNO) device, which aids asthma diagnosis and management.

Jason Smith, CEO at Bedfont® Scientific, said, “WHX Dubai continues to set the benchmark for healthcare innovation worldwide. Our presence underscores our dedication to excellence and to delivering devices that genuinely elevate the standard of patient care. As healthcare demands grow, we remain committed to providing solutions that empower clinicians, improve outcomes, and support a more efficient, responsive care environment. We look forward to building on the momentum generated at this year’s event.”

WHX Dubai 2026 is expected to attract over 235,000 professionals, offering the opportunity to see innovative medical solutions, attend educational and thought-leadership conferences, and network with like-minded individuals looking to improve healthcare across the globe. With strong relationships already established across the Middle East, Bedfont® hopes to engage with various healthcare professionals during the event, showcasing its innovative breath analysis devices.

You will find the friendly Bedfont® team at stand S7.F90.F. For more information on Bedfont® and to learn more about the Smokerlyzer®, Gastrolyzer®, and NObreath® devices, visit the website here.

New year, new you: setting quit goals with carbon monoxide (CO) monitoring.

Posted on

January marks the start of a new year, with many people using this time as a fresh start and the perfect time to set health-improving goals. A study in 2024 found that January is the most popular month of the year for people to give up smoking, with an average of 440,670 online searches for terms related to quitting smoking1.

New Year’s resolutions can be health-focused or financially driven, and quitting smoking aligns perfectly with both. Not only does it improve overall health, but it also saves significant money, allowing people to achieve their financial goals.

Understanding CO monitoring.

Carbon monoxide is an odourless, colourless, and tasteless gas that is produced during incomplete combustion. This gas is found when smoking tobacco and has a profound effect on people’s health. When inhaled, CO binds to haemoglobin in red blood cells, reducing the delivery of oxygen throughout the body2. Smokers typically have high CO levels, and this can be monitored through a CO monitoring device used to aid a quit-smoking attempt.

The role of CO monitoring in quitting smoking.

A CO monitoring device, like the Smokerlyzer®, measures the levels of CO on exhaled breath, establishing a person’s smoking status. The device offers a simple test: the user exhales slowly into the device to receive an instant CO reading, providing tangible feedback. Using a CO monitoring device during a quit attempt empowers the user to take control of their own health and, by seeing their CO levels drop over time, motivates them to continue their quit attempt.

The Smokerlyzer® range.

  • Micro+™ – a CO breath and foetal %COHb %FCOHb device providing instant results, in parts per million (ppm), to help people stop smoking.
  • piCO™ – a breath CO device, providing instant results in exact ppm and %COHb to help people stop smoking.
  • piCObaby™ – a breath CO device for pregnant women to help them stop smoking, providing instant results in exact ppm, %COHb and %FCOHb.
  • iCOquit® – a personal CO device, which can be used at home to help you quit smoking.

Setting realistic quit goals.

Quitting smoking doesn’t happen instantly; it is a process, and like any significant lifestyle change, it works best when you set clear, achievable goals. A structured approach can help you stay focused, track progress, and celebrate success along the way. A helpful way to plan your quit journey is to make your goals SMART.

  • Specific – Be clear about what you want to achieve.
  • Measurable – Use CO readings or smoke-free days to track progress.
  • Achievable – Set goals that challenge you but are realistic.
  • Relevant – Focus on why quitting matters to you.
  • Time-bound – Set a timeframe for your targets.

Tracking progress and staying motivated.

Measuring CO levels during a quit attempt provides users with visual feedback; watching CO levels drop is a powerful motivator that helps people continue their journey. CO monitoring is also helpful in identifying relapses early and prompting users to get back on track. Quitting smoking is notoriously difficult, and it is important to celebrate milestones during a quit journey. Lower CO readings and smoke-free days are worth celebrating.

January provides the perfect opportunity to make positive, lasting changes, and quitting smoking is one of the most powerful steps you can take for your health. CO monitoring allows you to see tangible proof of your progress from the very first days of your quit journey. Watching CO levels drop is a reminder that your lungs are healing, your oxygen levels are improving, and your body is recovering.

Whether you are cutting down gradually or quitting altogether, setting clear goals, tracking your results, and celebrating each milestone can keep you motivated and on track. For more information on the Smokerlyzer® range and how it can aid a quit-smoking attempt, visit the website here.

References

  1. Leah. New study reveals the most popular times of year to quit smoking – Digital Health Technology News [Internet]. Digital Health Technology News. 2024 [cited 2025 Nov 6]. Available from: https://www.healthtechdigital.com/new-study-reveals-the-most-popular-times-of-year-to-quit-smoking/
  2. Cancer Research UK. What’s in a cigarette? [Internet]. Cancer Research UK. CRUK; 2023. Available from: https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/smoking-and-cancer/whats-in-a-cigarette-0

Bedfont® Scientific Limited Expands Global Access to FeNO Testing in India

Posted on

Rbeck Healthtech Private completes registration for the NObreath® FeNO device, helping to improve asthma care across the region.

Bedfont® Scientific Limited, world leaders in breath analysis, with over 48 years of experience in designing and manufacturing medical breath analysis devices, has collaborated with Rbeck Healtech Private to make Fractional exhaled Nitric Oxide (FeNO) testing more accessible in India. Rbeck Healthtech Private is an entirely diverse healthcare equipment distributor, with a portfolio specialising in pulmonology, cardiology, and rehabilitation. It has recently added the innovative NObreath® device to its offerings, expanding access to FeNO testing in India.

Asthma is a chronic lung disease which cannot be cured; however, with the correct diagnosis and treatment, people with asthma can lead normal lives. India accounts for approximately 13.1% of the global asthma burden1, meaning that improving access to essential diagnostic and management tools, such as the NObreath®, is vital. The NObreath® measures FeNO levels on exhaled breath, a key indicator in type 2 airway inflammation, which is commonly found in asthma.

Jason Smith, CEO at Bedfont®, comments, “Partnering with Rbeck Healthtech and the successful registration for the NObreath® in India is a meaningful milestone in our mission to make precision asthma care accessible worldwide. India faces a significant burden of asthma, and we believe that FeNO testing can empower clinicians with clearer insights into airway inflammation, leading to more personalised and effective treatment decisions.”

With the Global Asthma Report 2022 indicating that a considerable proportion of asthmatic individuals remain underdiagnosed or untreated2 in India, it is hoped that this strategic partnership will help expand the accessibility of FeNO testing in the region, ultimately saving lives.

To find out more about the NObreath® and how it is improving asthma care worldwide, visit the website here.

References

1.Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: the Global Asthma Network study. ERJ Open Research [Internet]. 2022 May 30;8(2):00528-2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149387/

2.The Global Asthma Report 2022 [Internet]. Globalasthmareport.org. 2022 [cited 2025 Oct 8]. Available from: https://globalasthmareport.org/regions/india.php?

Bedfont celebrates 45 years of business in 70’s style

Posted on

Local medical device manufacturer, Bedfont Scientific Ltd., returns to the era it all began for its 45th birthday

On 8th December, Kent Med-tech company, Bedfont Scientific Ltd. celebrated 45 years of business with a 1970’s themed party. The Bedfont Family celebrated with costumes from prominent 70’s characters, 70’s party games, 70’s party food, and a video tribute from a number of employees and distributors who have contributed to the business since 1976.

Jason Smith, Managing Director, remarks, “Back in 1976 the incidence of serious hazards related to medical gas supply systems was described as ‘alarming’. My favourite inspirational quote is ‘a pessimist sees the difficulty in every opportunity, an optimist sees the opportunity in every difficulty’ from Winston Churchill. I think this describes very aptly how my godfather, John Marron, went on to design and manufacture Bedfont’s first ever product; the TM3 Medi-Gas Check for ensuring gas supply systems were safe before use. This product undoubtedly saved lives and started Bedfont on a road of life-saving gas monitors. Back then, Bedfont employed one person and was based in a bedsit in London; now we employ 50 direct staff, have over 80 global distributors, and even have our own offices in Kent and Austria. We will continue to innovate new non-invasive breath analysis devices to bring these life-saving products into people’s homes worldwide, and hope to do so for the next 45 years!”

Kent Invicta Chamber of Commerce names Bedfont Scientific Ltd. as Innovative Business of the Year 2020/2021

Posted on

The KICC awards recognises Med-tech company, Bedfont’s innovative success

The long-awaited Kent Invicta Chamber of Commerce (KICC) awards took place on Thursday 18th November, and named medical device manufacturer, Bedfont, as Innovative Business of the Year.

The KICC awards, celebrated every year, brings together businesses across Kent, showcasing their amazing achievements. The awards had unfortunately been delayed due to COVID-19, but finally took place on Thursday at Westhanger Castle, Hythe, boasting an even more impressive evening than ever before.

Local medical technology business, Bedfont, was delighted to have received the accolade for Innovative business of the year. A multi-award winning medical device manufacturer, Bedfont is based in Harrietsham, Kent. Their products help to detect a range of medical conditions via breath analysis, removing the need for needles, blood samples, and long waiting time for results.

Managing Director, Jason Smith, explained, “It’s been a difficult couple of years, being a breath analysis device manufacturer during the Coronavirus pandemic – a disease spread by breath! However, Bedfont did what it does best; innovate. We adapted our products, resources, and services to better support both our employees and customers remotely and the Bedfont Family are over the moon to see that this has been recognised.”

Back to top